Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?

Nature Clinical Practice Nephrology volume 2, pages 72–73 (2006)Cite this article

boxed-textPisani A et al. (2005) Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 46: 120–127

Background

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Eng CM et al. (2001) Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345: 9–16

    Article  CAS  Google Scholar 

  2. Wilcox WR et al. (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75: 65–74

    Article  CAS  Google Scholar 

  3. Desnick RJ (online 7 September 2005) The phase 4 clinical trial demonstrates clinical benefit of Fabrazyme® (agalsidase beta) [http://www.acmg.net/resources/ACMG/2005/abs-group-04.pdf] (accessed 7 September 2005)

  4. Nakao S et al. (2003) Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int 64: 801–807

    Article  Google Scholar 

  5. Kosch M et al. (2004) Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int 66: 1279–1282

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Human Genetics, Mount Sinai School of Medicine of New York University, New York, NY, USA

    Maryam Banikazemi & Robert J Desnick

Authors
  1. Maryam Banikazemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J Desnick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J Desnick.

Ethics declarations

Competing interests

Dr. Desnick is a consultant to the Genzyme Corporation and an inventor on intellectual property licensed to the Genzyme Corporation. He is also a founder of, consultant to, and holder of options in Amicus Therapeutics, Inc. Dr Banikazemi has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Banikazemi, M., Desnick, R. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?. Nat Rev Nephrol 2, 72–73 (2006). https://doi.org/10.1038/ncpneph0100

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0100

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing